Andrew C Thorpe
Overview
Explore the profile of Andrew C Thorpe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
295
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ho M, Black A, Zargar H, Fairey A, Mertens L, Dinney C, et al.
Can Urol Assoc J
. 2023 Oct;
17(10):301-309.
PMID: 37851909
Introduction: Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). Cisplatin, however, can induce renal toxicity. Furthermore, RC is...
2.
Kirk P, Lotan Y, Zargar H, Fairey A, Dinney C, Mir M, et al.
J Urol
. 2023 Feb;
209(5):882-889.
PMID: 36795962
Purpose: While the presence of residual disease at the time of radical cystectomy for bladder cancer is an established prognostic indicator, controversy remains regarding the importance of maximal transurethral resection...
3.
Einerhand S, Black A, Zargar H, Fairey A, Dinney C, Mir M, et al.
World J Urol
. 2022 Sep;
40(11):2707-2715.
PMID: 36169695
Purpose: Cisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer (MIBC). However, up to 50% of patients are cisplatin ineligible. The aim of this...
4.
DAndrea D, Black P, Zargar H, Dinney C, Soria F, Cookson M, et al.
J Urol
. 2021 Aug;
207(1):70-76.
PMID: 34445891
Purpose: We investigated the pathological response rates and survival associated with 3 vs 4 cycles of cisplatin-based neoadjuvant chemotherapy (NAC) in patients with cT2-4N0M0 muscle invasive bladder cancer. Materials And...
5.
DAndrea D, Black P, Zargar H, Zargar-Shoshtari K, Soria F, Fairey A, et al.
World J Urol
. 2021 Aug;
39(12):4345-4354.
PMID: 34370078
Purpose: To assess the association of patient age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer (MIBC). Materials And Methods: We analyzed data from 1105 patients with...
6.
Soria F, Black P, Fairey A, Cookson M, Yu E, Kassouf W, et al.
BJU Int
. 2020 Nov;
128(1):79-87.
PMID: 33152179
Objectives: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis. Patients And...
7.
DAndrea D, Matin S, Black P, Petros F, Zargar H, Dinney C, et al.
BJU Int
. 2020 Sep;
127(5):528-537.
PMID: 32981193
Objective: To assess the differential response to neoadjuvant chemotherapy (NAC) in patients with urothelial carcinoma of the bladder (UCB) compared to upper tract urothelial carcioma (UTUC) treated with radical surgery....
8.
DAndrea D, Black P, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey A, et al.
Urol Oncol
. 2020 Feb;
38(7):639.e1-639.e9.
PMID: 32057595
Objective: To assess the effect of patient's sex on response to neoadjuvant chemotherapy (NAC) in patients with clinically nonmetastatic muscle-invasive bladder cancer (MIBC). Methods: Complete pathologic response, defined as ypT0N0...
9.
Black A, Zargar H, Zargar-Shoshtari K, Fairey A, Mertens L, Dinney C, et al.
Urol Oncol
. 2019 Nov;
38(1):3.e17-3.e27.
PMID: 31676278
Introduction: The neutrophil-to-lymphocyte ratio (NLR) is an attractive marker because it is derived from routine bloodwork. NLR has shown promise as a prognostic factor in muscle invasive bladder cancer (MIBC)...
10.
Mafeld S, Vasdev N, Patel A, Ali T, Lane T, Boustead G, et al.
BJU Int
. 2014 Nov;
116(4):538-45.
PMID: 25410715
We present a review on the increasing indications for the use of positron emission tomography (PET) in uro-oncology. In this review we describe the details of the different types of...